Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.46 |
| ▸ | KDM5A | P29375 | 2/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9499593 | 0.85 | HTR6 (0.65) | HTR6KDM4CKDM5AKDM5BPDPK1 | |
| SCHEMBL1568036 | 0.81 | KDM4C (0.53) | HTR6KDM4CKDM5AKDM5BPDPK1 | |
| SCHEMBL315200 | 0.78 | HTR6 (0.69) | HTR6KDM4C | |
| SCHEMBL315259 | 0.78 | HTR6 (0.82) | HTR6 | |
| SCHEMBL12428551 | 0.77 | KDM4C (0.45) | HTR6KDM4CKDM5AKDM5BPDPK1 | |
| SCHEMBL10469025 | 0.76 | HTR6 (0.59) | HTR6KDM4CKDM5AKDM5BPDPK1 | |
| SCHEMBL3902319 | 0.76 | HTR6 (0.59) | HTR6 | |
| SCHEMBL3912579 | 0.76 | HTR6 (0.62) | HTR6 | |
| SCHEMBL9499994 | 0.76 | HTR6 (0.54) | HTR6 | |
| SCHEMBL17257943 | 0.75 | KDM4C (0.50) | KDM4CKDM5AKDM5BPDPK1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981923-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100130742-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HARRIS III RALPH NEW | 2010-05-27 | — | — | US | disclosed |
| US-7671235-B2 | N-[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-N-methyl-methanesulfonamide; 5-HT6 and 5-HT2A receptor modulators; selectiveserotonin reuptake inhibitors; selective seotonin receptor antagonists;gastrointestinal disorders; irritable bowel syndrome; cental nervous system | ROCHE PALO ALTO LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7531577-B2 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531577-B2 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | HTR6, TPH1, HTR1B | HTR6 1/4885KDM4C 4108/4885KDM5A 4023/4885 |
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | INSRR, TTN, INSR | HTR6 1360/4885KDM4C 4729/4885KDM5A 4846/4885 |
| US-20100130742-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, TTN, INSR | HTR6 1360/4885KDM4C 4729/4885KDM5A 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.